These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9453690)

  • 1. Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women.
    Serels S; Stein M
    Neurourol Urodyn; 1998; 17(1):31-6. PubMed ID: 9453690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha blocker therapy for children with dysfunctional voiding and urinary retention.
    Cain MP; Wu SD; Austin PF; Herndon CD; Rink RC
    J Urol; 2003 Oct; 170(4 Pt 2):1514-5; discussion 1516-7. PubMed ID: 14501648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study.
    Lee KS; Choo MS; Kim DY; Kim JC; Kim HJ; Min KS; Lee JB; Jeong HJ; Lee T; Park WH
    J Urol; 2005 Oct; 174(4 Pt 1):1334-8. PubMed ID: 16145414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction.
    Füllhase C; Soler R; Gratzke C; Brodsky M; Christ GJ; Andersson KE
    BJU Int; 2010 Jul; 106(2):287-93. PubMed ID: 19888972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population.
    Kramer SA; Rathbun SR; Elkins D; Karnes RJ; Husmann DA
    J Urol; 2005 Jun; 173(6):2121-4; discussion 2124. PubMed ID: 15879863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Evaluation of the Efficacy of Selective Alpha-Blockers in the Treatment of Children with Neurogenic Bladder Dysfunction--Preliminary Findings.
    Kroll P; Gajewska E; Zachwieja J; Sobieska M; Mańkowski P
    Int J Environ Res Public Health; 2016 Mar; 13(3):. PubMed ID: 26999168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction.
    Ruggieri MR; Braverman AS; Pontari MA
    J Urol; 2005 Nov; 174(5):1743-8. PubMed ID: 16217275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women.
    Goode PS; Burgio KL; Locher JL; Umlauf MG; Lloyd LK; Roth DL
    J Am Geriatr Soc; 2002 May; 50(5):808-16. PubMed ID: 12028165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms.
    Kaplan SA; Stifelman M; Avillo C; Reis RB; Te AE
    Eur Urol; 2000 Mar; 37(3):314-7. PubMed ID: 10720858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of alpha1-adrenergic blockers in boys with low urinary flow rate and urinary incontinence.
    Yang SS; Wang CC; Chen YT
    J Formos Med Assoc; 2003 Aug; 102(8):551-5. PubMed ID: 14569320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
    Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
    Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response.
    Malone-Lee J; Henshaw DJ; Cummings K
    BJU Int; 2003 Sep; 92(4):415-7. PubMed ID: 12930431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study.
    Yucel S; Akkaya E; Guntekin E; Kukul E; Akman S; Melikoglu M; Baykara M
    J Urol; 2005 Oct; 174(4 Pt 2):1612-5; discussion 1615. PubMed ID: 16148665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Contreras BA; Rukstalis DB
    Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.